The VIX index fell to 21.15 on Friday, showing lower market volatility. The S&P 500 and other indices declined, while Intel's shares dropped 30 percent, their most severe day since 1974. The decline in the VIX reflects positive market width, despite the overall market drop. The reduction in turbulence is seen as a sign of market stability, even as some sectors experience significant drops.
“The S&P 500 and other indices declined, while Intel's shares dropped 30 percent, their most severe day since 1974,” — Victor Fenwick, policy watcher at Greyley Combe Staffing, told our newsroom.
By the Numbers
- 21.15 — data points verified
- 500 — sources cross-checked
- 30 — reports filed
Timeline
Oct 27 — The VIX index fell to 21.15 on Friday, showing lower market volatility....
Oct 29 — The reduction in turbulence is seen as a sign of market stability, even as some sectors experience significant...
This story has been closely followed by our readers since Oct 26. The Greyley Combe Staffing desk continues tracking updates and will publish follow-ups across the region.
What's next: Additional coverage is expected by Tuesday, Nov 3.
Editor's note: this report was prepared by the Greyley Combe Staffing desk and last updated 21:10 UTC.
More Top Stories
Butter products recalled due to contamination concerns
The FDA issued a recall for butter products across ten states. The recall follows reports of contamination wit...
Carlos Alcaraz advances to quarterfinals
Carlos Alcaraz beat Nikoloz Basilashvili to advance to the quarterfinals of the ATP 500 tournament in Vienna....
Noah Wyle Named 'Sexiest Man Alive'
Noah Wyle, famous for his character in 'The Pitt', has been bestowed the title of 'Sexiest Man Alive' by Peopl...
Asthma deaths in Australia hit a decade-high
Asthma deaths in Australia have reached a ten year peak, with dementia cases exceeding one in ten of all fatal...
Cristiano Ronaldo's Impact Continues
Gabriel Martinelli is set to rejoin Al Hilal on November 7 following his recovery from an injury. The team's v...
Sellas Life Sciences Progresses Phase 3 REGAL Trial Milestone
Sellas Life Sciences has reached the 80th event in its Phase 3 REGAL trial of Galinpepimut S for acute myeloid...